Biomark Diagnostics Inc. (CSE:BUX)
Canada · Delayed Price · Currency is CAD 0.3700
0.00 (0.00%)
Aug 12, 2025, 12:44 PM EDT
Biomark Diagnostics Company Description
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer.
The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer.
It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers.
The company was incorporated in 2014 and is headquartered in Richmond, Canada.
Biomark Diagnostics Inc.
| Country | Canada |
| Founded | 2014 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| CEO | Rashid Ahmed Bux |
Contact Details
Address: 3851 Shell Road Richmond, British Columbia V6X 2W2 Canada | |
| Phone | 604 370 0779 |
| Website | biomarkdiagnostics.com |
Stock Details
| Ticker Symbol | BUX |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | April - March |
| Reporting Currency | CAD |
| ISIN Number | CA09073K1084 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Rashid Ahmed Maula Bux B.Sc., MBA | Founder, Chief Executive Officer, President and Director |
| Guoyu Huang MBA | Chief Financial Officer |
| Brian Kai-Ming Cheng B.Sc., M.Sc, M.Sc. | Chief Technical Officer and Independent Director |
| Dr. Jeff Haince Ph.D. | GM and Chief Scientific Officer |